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Background: Tumor tissue is composed of variable numbers of
cancer cells and stromal cells, and tumor-associated macrophages
are recruited into cancer-induced stroma and produce a specific
microenvironment. Alternatively, activated macrophages (M2 phe-
notype) are known to be related to tumor progression and outcome,
and CD204 has been reported to be expressed in M2 macrophages in
some tumors.
Methods: To investigate whether CD204-positive macrophages
reflect tumor aggressiveness in adenocarcinoma of the lung, we
investigated the relationships between the numbers of CD204-
positive stromal macrophages and both clinicopathological features
and outcome in 170 consecutive resected cases. We also examined
the relationships between the numbers of CD204-positive macro-
phages and the expression levels of cytokines involved in the
migration and differentiation of M2 macrophages.
Results: The numbers of CD204-positive macrophages were signif-
icantly correlated with several prognostic factors. The log-rank test
showed a significant association between the numbers of CD204-
positive macrophages and a poor outcome (p 0.0073), whereas the
numbers of macrophages expressing CD68, a pan-macrophage/
monocyte marker, were of marginal prognostic significance (p 
0.0789). We evaluated associations between the levels of expression
of the cytokines IL-6, IL-10, IL-12a, IL-12b, M-colony-stimulating
factor, IFN-gamma-., and monocyte chemoattractant protein-1 in
cancer tissue and the numbers of CD204-positive macrophages. The
expression levels of IL-10 and monocyte chemoattractant protein-1,
which are involved in differentiation, accumulation, and migration
of M2 macrophages, were significantly correlated with the numbers
of CD204-positive macrophages (p  0.031 and p  0.031, respec-
tively).
Conclusion: These findings demonstrated that CD204-positive mac-
rophages clearly reflect the tumor-promoting phenotype of tumor-
associated macrophages in lung adenocarcinoma.
Key Words:Macrophage, Tumor-associated macrophages (TAMs),
Lung cancer, Stroma, CD204.
(J Thorac Oncol. 2010;5: 1507–1515)
Tumor tissue is composed of variable numbers of cancercells and stromal cells, and the cancer cells interact with
the surrounding stromal cells and produce a specific micro-
environment that is capable of influencing tumor progres-
sion.1 Macrophages are the most abundant cancer stromal
cells involved in the host immune system,2 and in several
kinds of cancer, tumor-associated macrophage (TAM) infil-
tration has been found to be correlated with a poor out-
come.3–7 Macrophages have two different functions, a tumor-
suppressive (M1) function and a tumor-supportive (M2)
function.8,9 M1 macrophages are characterized by high ex-
pression of proinflammatory cytokines, including IL-1, IL-6,
IL-12, and tumor necrosis factor (TNF), whereas tumor
supportive macrophages (M2), which are characterized by
IL-4high, IL-10high, and IL-12low, play important roles in
tumorigenesis, angiogenesis, matrix remodeling, and metas-
tasis.10 Recent studies have revealed high expression of
CD204 in M2 macrophages.11–13
Several factors related to TAM recruitment and differ-
entiation have been reported. IL-4 and IL-10 are known to
polarize macrophages toward the M2 phenotype, and macro-
phage colony-stimulating factor (M-CSF, also known as
CSF-1) and monocyte chemoattractant protein-1 (MCP-1,
also known as CCL2) have been implicated in M2 macro-
phage polarization, differentiation, and migration. On the
other hand, classically activated M1 macrophages, which are
generally considered to be potent effector cells that defend
the body against pathogens and tumor cells, are induced by
IFN-gamma-. alone or in concert with microbial stimuli or
cytokines such as tumor necrosis factor and granulocyte
macrophage-CSF.10
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Lung cancer is the most common cause of cancer
deaths worldwide,14 and adenocarcinoma accounts for more
than half of all non-small cell lung carcinomas.15 Although
surgery is the only means of radical cure, because the 5-year
disease-free survival rate for adenocarcinoma of the lung
after curative resection is less than 70%,15 the development of
new effective therapeutic modalities targeting the tumor mi-
croenvironment is needed. Because investigators, including
ourselves, have reported finding a correlation between the
grade of macrophage infiltration and the malignancy of ade-
nocarcinoma of the lung,7,16,17 targeting M2 macrophages
would be a novel approach to the treatment of lung adeno-
carcinoma.
Thus far, TAMs have been mainly assessed by CD68
immunostaining, but CD68 is a broad TAM marker that
cannot discriminate the M2 phenotype from other TAM
phenotypes. Recent studies have reported strong expression
of CD204 by M2 macrophages, and using CD204 (scavenger
receptor class A) as a marker has revealed that invasion by
CD204-positive macrophages is related to tumor progression
and outcome in glioma, ovarian epithelial tumors, and pan-
creatic cancer.11–13,18 CD204 is the prototypic member of an
expanding family of membrane receptors collectively termed
scavenger receptors and a multifunctional receptor that rec-
ognizes many different types of negatively charged macro-
molecules.19 The aim of this study was to examine whether
CD204 can be used to detect the tumor-promoting subtype of
macrophages in lung adenocarcinoma.
PATIENTS AND METHODS
Patients
Between January 1996 and March 1998, a total of 201
patients with lung adenocarcinoma underwent surgery with
curative intent at the National Cancer Center Hospital East,
Chiba, Japan, and after excluding the 31 cases whose surgical
specimen was of poor quality, the remaining 170 cases were
included in this study. All patients signed an institutional
TABLE 1. Relationship Between CD68()/CD204() Macrophage and
Clinicopathological Features
Variables
CD68 CD204
Low
(n  82)
High
(n  88) p*
Low
(n  81)
High
(n  89) p*
Age (yr)
70 55 67 0.190 55 67 0.286
70 27 21 26 22
Gender
Male 31 54 0.002† 27 58 0.001†
Female 51 34 54 31
Smoking history
Never 53 28 0.001† 56 25 0.001†
Former or current 29 60 25 64
Differentiation
Well 59 27 0.001† 66 20 0.001†
Moderately or poorly 23 61 15 69
Pathological stage
IA 57 38 0.001† 59 36 0.001†
IB–IIIA 25 50 22 53
T status
T1 62 47 0.003† 61 48 0.004†
T2–3 20 41 20 41
Nodal involvement
N() 70 60 0.008† 76 54 0.001†
N() 12 28 5 35
Lymphatic permeation
Ly() 65 43 0.001† 63 45 0.001†
Ly() 17 45 18 44
Vessel invasion
V() 62 43 0.001† 64 41 0.001†
V() 20 45 17 48
Pleural invasion
PL() 71 50 0.001† 68 53 0.001†
PL() 11 38 13 36
*Pearson 2 test.
†p  0.05.
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review board-approved informed consent. The tumors were
staged according to the tumor-node-metastasis classification
of the International Union Against Cancer (UICC). Mean age
at the time of surgery was 62 years (range: 33–85 years), and
the median follow-up period was 10.1 years. Survival time
was measured from the date of surgery.
Histopathology Studies
All surgical specimens were fixed with 10% formalin
and embedded in paraffin wax. The tumors were cut at
approximately 5-mm intervals, and serial 4-m sections were
stained with hematoxylin and eosin and by the Alcian blue-
periodic acid Schiff method to visualize cytoplasmic mucin
production and the Verhoeff-van-Gieson method to visualize
elastic fibers. Lymphatic permeation and pulmonary metas-
tasis were evaluated in sections stained with hematoxylin and
eosin. Vascular invasion and pleural invasion were evaluated
by the Verhoeff-van-Gieson method. Two observers (Y.O.
and G.I.) who are unaware of the clinical data independently
reviewed all pathologic slides. The histologic diagnoses were
based on the third revised World Health Organization histo-
logic classification, and all the tumors are divided according
the predominant subtype into four groups: a bronchioloalveo-
lar carcinoma (BAC) group, papillary pattern (including mi-
cropapillary pattern) group, acinar pattern group, and solid
adenocarcinoma with mucin production pattern group. The
numbers of each predominant histologic subtype were BAC,
69; papillary, 50; acinar, 20; and solid, 31.
Tumor size was measured as the maximal diameter of
the tumor on the cut sections. The pathologic stage was
determined according to the classification of the UICC.
Evaluation of Clinicopathological Factors
Clinical characteristics were retrieved from the clinical
records available. The following clinicopathological factors
were investigated retrospectively to assess their impact on
survival: age (70 years versus70 years), gender, smoking
history (never smokers versus smokers), preoperative serum
carcinoembryonic antigen value (5.0 ng/ml versus 5.0
ng/ml), grade of differentiation (well differentiated versus
moderately or poorly differentiated), pathologic stage (IA
versus IB, II, and IIIA), pathologic T status (T1 versus T2,
T3), pathologic nodal involvement (positive versus negative),
lymphatic permeation (present versus absent), vascular inva-
sion (present versus absent), and pleural invasion (present
versus absent) (Table 1).
Antibodies and Immunohistochemistry
After reviewing the hematoxylin- and eosin-stained
slides of the surgical specimens, the block containing the
most extensive tumor component was selected from each
specimen. The slides were deparaffinized in xylene, dehy-
drated in a graded ethanol series, and after washing with
distilled water, the sections were placed in 0.1 M citric acid
buffer. For antigen retrieval, the slides were heated twice at
95°C for 20 minutes in a microwave oven (H2800 Microwave
Processor, Energy Beam Sciences Inc.) and then allowed to
cool for 1 hour at room temperature. Next, the slides were
washed 3 times in phosphate-buffered saline (PBS) and
immersed in a 0.3% hydrogen peroxide solution in methanol
for 15 minutes to inhibit endogenous peroxidase activity.
After washing the slides 3 times in PBS, nonspecific binding
was blocked by preincubation with 2% normal swine serum
in PBS (blocking buffer) for 30 minutes at room temperature.
Individual slides were then incubated overnight at 4°C with
mouse antihuman CD68 antibody (Dako, Japan) at a final
dilution of 1:100 in the blocking buffer and mouse antihuman
CD204 antibody (Scavenger Receptor class A-E5; Trans-
genic, Japan) at a final dilution of 1:100 in the blocking
buffer. The slides were again washed three times with PBS
and then incubated with EnVision (Dako, Denmark) for 1
TABLE 2. RNA Primers Used
Target Primer Sequence(5-3) Gene Size Products (bp) Position
Accession
Number
IL-6 Forward AAGCCAGAGCTGTGCAGATGAGTA 1131 150 (480–629) 554 NM_000600.2
Reverse TGTCCTGCAGCCACTGGTTC
IL-10 Forward GAGATGCCTTCAGCAGAGTGAAGA 1629 114 (193–306) 249 NM_000572.2
Reverse AGGCTTGGCAACCCAGGTAAC
IL-12a (p35) Forward AGGAATGTTCCCATGCCTTCAC 1444 170 (413–582) 497 NM_000882.2
Reverse CCAATGGTAAACAGGCCTCCAC
IL-12b (p40) Forward GGAGCGAATGGGCATCTGT 2347 112 (998–1109) 1053 NM_002187
Reverse TGGGTCTATTCCGTTGTGTCTTTA
M-CSF (CSF-1) Forward TAGCCACATGATTGGGAGTGGA 2973 88 (530–617) 573 NM_000757.4
Reverse CTCAAATGTAATTTGGCACGAGGTC
IFN-gamma-. Forward CTTTAAAGATGACCAGAGCATCCAA 1240 189 (372–560) 466 NM_004918
Reverse GGCGACAGTTCAGCCATCAC
MCP-1 (CCL2) Forward GCTCATAGCAGCCACCTTCATTC 760 147 (106–252) 179 NM_002982.3
Reverse GGACACTTGCTGCTGGTGATTC
GAPDH Forward GCACCGTCAAGGCTGAGAAC 1310 142 (248–389) 318 NM_002046
Reverse ATGGTGGTGAAGACGCCAGT
CSF, colony-stimulating factor; MCP, monocyte chemoattractant protein; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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hour at room temperature, and after extensive washing with
PBS, the color reaction was developed in 2% 3, 3-diamino-
benzidine in 50 mM Tris-buffer (pH 7.6) containing 0.3%
hydrogen peroxidase. Finally, the sections were counter-
stained with Meyer hematoxylin, dehydrated, and mounted.
Immunostained cell counts were made blind to the
patients’ clinical data. Round cells in the stroma of the cancer
tissue were counted as macrophages. Two pathologists (Y.O.
and G.I) counted CD68- and CD204-positive macrophages in
high-power microscopic fields (400; 0.0625 mm2), and
reviewed all slides.
Tissue Samples, RNA Extraction, Reverse
Transcription, and Real-Time Polymerase Chain
Reaction
Total RNA were extracted from 18 patients with ade-
nocarcinoma surgically resected at Thoracic Oncology Divi-
sion, National Cancer Center Hospital East. Samples of
cancer tissue and noncancer tissue in the most remote part of
the same lobe of the lung as the cancer were collected and
immediately homogenized in Trizol reagent (Invitrogen, CA)
with multibeads shocker (Yasui Kikai) and stored at 80°C
until used. Total RNA was isolated from the tissues by using
a commercial RNA isolation reagent according to the manu-
facturer’s instructions.
The RNA was reverse transcribed to synthesize cDNA
by using a primerscript RT reagent kit according to the
manufacturer’s instructions (Takara Biochemicals, Osaka,
Japan).
To quantitatively compare the mRNA level of each
cytokine, we performed real-time polymerase chain reaction
using SYBR Premix Ex TaqII (Takara, Japan) with Smart
Cycler II (Takara Biochemicals, Osaka, Japan) according to
the manufacturer’s protocol. The sense and antisense primers
used for quantitative amplification of cytokine mRNAs (IL-6,
IL-10, IL-12a, IL-12b, M-CSF, IFN-gamma-., and MCP-1)
and for amplification of glyceraldehyde-3-phosphate dehy-
drogenase as an internal control are shown in Table 2.
The amount of template cDNA was expressed by a
threshold cycles (G) that was determined from the amplifi-
cation curve (exponential curve) and a threshold level of
polymerase chain reaction product detection. One G was
equal to a twofold difference in initial template. The quanti-
fication data were analyzed with Smart Cycler System Soft-
ware version 2.0d (Cepheid). The level of expression of each
gene is reported as the ratio of its expression to the level of
glyceraldehyde-3-phosphate dehydrogenase gene expression
in the same sample. The ratio between the level of cytokine
expression in the cancer tissue to its level of expression in the
noncancer tissue was calculated in each case, and the median
number of CD204-positive macrophages was used to divide
the cases into a high CD204-positive macrophage group
(above the median value) and a low CD204-positive macro-
phage group (below the median value).
Statistical Analysis
The correlations between the grade of expression of
CD68 and CD204 in cancer stromal cells and the clinicopath-
FIGURE 1. Immunostaining of stro-
mal CD68 macrophages (A and B)
and CD204 macrophages (C and D).
A, CD68 macrophages (low number),
(B) CD68 macrophages (high num-
ber), (C) CD204 macrophages (low
number), and (D) CD204 macro-
phages (high number).
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ological factors were evaluated by the 2 test. Comparison of
the numbers of CD68-positive macrophages and CD204-
positive macrophages in each predominant subtype group
was performed by one-way layout analysis of variance. All
pairs of groups were compared by using the Bonferroni test.
Overall survival was measured from the date of surgery to the
date of death from any cause or to the date the patient was last
known to be alive. Survival curves were estimated by the
Kaplan-Meier method, and differences in survival were com-
pared by the log-rank test. Differences of the ratios of
expression of each cytokine between high and low CD204-
positive macrophage group were tested for statistical signif-
icance by the Mann-Whitney U test. The distribution of
CD204-positive macrophages and CD68-positive macro-
phages and the distribution of CD204 expression and ratios of
expression of each cytokine were tested for correlations by
calculating Spearman rank correlation coefficients. A p value
less than 0.05 was considered significant. Statistical analysis
software (SPSS, Version 11.0) was used to perform the
analyses.
RESULTS
CD68-Positive Macrophages and CD204-
Positive Macrophages in Cancer Stroma
A series of 170 specimens of adenocarcinoma of the
lung were examined for CD68 and CD204 expression in the
cancer stroma (Figures 1A–D). The distribution of CD204-
positive macrophages and CD68-positive macrophages in
each tumor was strongly correlated (p  0.001, r2  0.5910)
(Figure 2A). The mean number of CD68-positive macro-
phages and CD204-positive macrophages was 30.6  1.8
(median: 25, range: 0–120) and 24.8  2.0 (median: 15,
range: 0–143), respectively (Figure 2B).
Correlations Between the Numbers of CD68-
Positive Macrophages and CD204-Positive
Macrophages and the Clinicopathological
Factors
The median numbers of infiltrating macrophages were
used to divide the cases into two groups: high; above the
median value, low; below the median value. The relationship
between the two groups and the individual clinicopathologi-
cal features are shown in the Table 1. Both CD68 expression
and CD204 expression were significantly correlated with
gender, smoking history, tumor differentiation, pathologic
stage, pathologic T status, pathologic nodal involvement,
lymphatic permeation, vascular invasion, and pleural inva-
sion.
Correlations Between the Numbers of CD68-
Positive Macrophages and CD204-Positive
Macrophages and the Predominant Histologic
Subtype
The relationships between the numbers of infiltrating
macrophages and predominant histologic subtypes are shown
in the Figure 3. The average numbers of CD68-positive
macrophages according to predominant subtype were BAC,
18; papillary, 30; acinar, 38; and solid, 55, and the numbers
were significantly higher in the predominantly papillary sub-
type (p  0.004), the predominantly acinar subtype (p 
0.001), and the predominantly solid subtype (p 0.001) than
in the BAC subtype (Figure 3A). The average numbers of
CD204-positive macrophages according to predominant sub-
type were BAC, 11; papillary, 24; acinar, 32; and solid, 51,
and the numbers were significantly higher in the predomi-
nantly papillary subtype (p  0.008), the predominantly
acinar subtype (p  0.001), and the predominantly solid
subtype (p  0.001) than in the BAC subtype (Figure 3B).
The numbers of CD68-positive macrophages and CD204-
positive macrophages were both significantly higher in the
solid subtype than in the papillary subtype (p  0.001 and
p  0.010, respectively) and acinar subtype (p  0.001 and
p  0.018, respectively).
FIGURE 2. Distribution of CD68 and CD204 macro-
phages. A, Correlations between the distribution of CD68
macrophages and CD204 macrophages of each case are
shown. The numbers of CD204 macrophages were signifi-
cantly correlated with the numbers of CD68 macrophages
(r2  0.5910, p  0.001). B, The mean number of CD68-
positive macrophages and CD204-positive macrophages was
30.6  1.8 (median: 25, range: 0–120) and 24.8  2.0
(median: 15, range: 0–143), respectively.
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Relationship Between the Numbers of CD68-
Positive Macrophages and CD204-Positive
Macrophages and Overall Survival
Univariate analyses by the log-rank test were per-
formed to compare survival according to numbers of infil-
trating macrophages (Table 3), and overall survival curves
obtained by the Kaplan-Meier method, with statistical signif-
icance assessed using the log-rank test, are shown in Figure 4.
Although Survival time was significantly shorter in the high
CD204-positive macrophage group (CD204high group) (p 
0.0073), CD68high did not significantly show prognostic im-
pact compared with CD68low (p  0.0789). Age (p  0.048),
gender (p  0.0019), smoking history (p  0.0002), CEA
(p  0.0150), differentiation (p  0.001), pathologic stage
(p  0.001), pathologic T status (p  0.001), nodal involve-
ment (p  0.001), lymphatic permeation (p  0.001), vessel
invasion (p  0.001), and pleural invasion (p  0.001) were
also correlated with shorter survival time.
Although we stratified the patient with age (70 years
or 70 years), we could observe the significant survival
difference between CD204high group and CD204 low group
only in the group of more than 70 years (p  0.01). In the
group of less than 70 years, we could not observe significant
difference (p  0.05). Correspondingly, when stratified with
pathologic stage (IA or IB–IIIA), significant differences be-
tween CD204high group and CD204 low group could not be
observed: IA, p 0.25; IB–IIIA, p 0.41, respectively (data
not shown).
Correlations Between the Numbers of CD204-
Positive Macrophages and Cytokine Expression
in Cancer Tissues
To identify factors associated with the migration and
differentiation of M2 macrophages, we examined the expres-
sion of IL-6, IL-10, IL-12a, IL-12b, M-CSF, granulocyte
macrophage-CSF, IFN-gamma-., and MCP-1 and the number
of CD204-positive macrophages in specimens of adenocarci-
noma of the lung. The results showed that the ratios of
expression of IL-10 and MCP-1 in cancer tissue to their level
of expression in noncancer tissue (n  18) were significantly
higher in the CD204high group (p  0.031 and p  0.031,
respectively) (Figure 5A). The differences between the two
groups in expression of the other soluble factors, i.e., IL-6,
IL-12a, IL-12b, M-CSF, and IFN-gamma-. were not signifi-
cant. Although the IL-4 RNA levels were measured, the
amount of RNA expressed was too small to be studied (data
not shown).
Correlation analysis of the numbers of CD204-positive
macrophages and levels of IL-10 and MCP-1 expression
revealed that the numbers of CD204-positive macrophages
were significantly correlated with the increases in level of
IL-10 and MCP-1 (Figure 5B) (MCP-1: r2  0.641; IL-10:
r2  0.580).
DISCUSSION
In this study, we first showed that the numbers of
CD204-positive macrophages were correlated with several
clinicopathological factors in lung adenocarcinoma, i.e., gen-
der, smoking history, tumor differentiation, pathologic stage,
T status, nodal involvement, lymphatic permeation, vessel
invasion, and pleural invasion. The grade of CD204 expres-
sion was significantly correlated with cumulative survival,
and the levels of expression of IL-10 and MCP-1, which are
involved in polarization of M2 macrophages, were signifi-
cantly correlated with the numbers of CD204-positive mac-
rophages. These results suggest that CD204-positive macro-
phages could be the tumor-promoting macrophages (M2
macrophages) involved in tumor progression in lung adeno-
carcinoma.
Macrophage number has been shown to have prognos-
tic significance in lung adenocarcinoma, but the immunohis-
tochemical identification in those studies involved the use of
antibodies against CD68.7,16,17,20 In our study, we also used
an antibody against CD204, and the numbers of CD204-
FIGURE 3. Numbers of CD68 macrophages
(A) and CD204 macrophages (B) in each his-
tologically predominant subtype (bronchioloal-
veolar carcinoma [BAC], papillary, acinar, and
solid).
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positive macrophages allowed for better prognostic distinc-
tion than the grade of CD68-positive macrophages. This
finding suggests that CD204 could outline the macrophages
that promote tumor progression and affect the prognosis more
clearly, thereby allowing for a more precise assessment of the
density of the aggressive subpopulation of M2 macrophages.
Although CD68 is known as a pan-monocyte/macrophage
marker,21 not all TAMs may be stained by CD68. The
difference in staining patterns may be due to the phenomenon
of monocyte/macrophage heterogeneity,22 because different
subgroups of macrophages were identified by each antibody.
We also demonstrated that the quantities of MCP-1 and
IL-10 were significantly correlated with the numbers of
infiltrating CD204-positive macrophages within the cancer-
induced stroma and that other cytokines, i.e., IL-4, IL-6,
IL-12, M-CSF, and IFN-gamma-., were not significantly
correlated with the numbers of CD204-positive macrophages.
MCP-1 is known to polarize, differentiate, and migrate M2
macrophages,23,24 and IL-10 is known to function to polarize
monocytes to M2 macrophages.11 Both MCP-1 and IL-10 are
derived from M2 macrophages themselves and from tumor
cells.25,26 We have previously shown that stromal MCP-1
rather than tumoral MCP-1 contributes to macrophage re-
cruitment in breast cancer suggesting that stromal MCP-1
may recruit additional macrophages through tumor cell-mac-
rophage interactions.27 Zeni et al.28 immunohistochemically
demonstrated that IL-10 is expressed by macrophages and not
by tumor cells in patients with non-small cell lung cancer,
and IL-10 expression correlated with disease progression and
the patients’ outcome. These findings led us to surmise that
MCP-1 and IL-10 derived from tumor cells induce differen-
tiation, accumulation, and migration of M2 macrophages,
which contribute to recruiting more CD204-positive macro-
phages in lung cancer tissue. IL-4 has been found to polarize
macrophages, but too little IL-4 was expressed to be detected
in this study.
The results of this study demonstrated that CD204-
positive macrophages are engaged in histologic predominant
subtype. Macrophage infiltration in the solid subtype was
correspondingly much greater than in the BAC subtype.
Actually, adenocarcinoma with a predominant solid subtype
has been found to be correlated with certain gene profiles and
a poorer outcome,29 implying that this type of adenocarci-
noma belongs to another biologic spectrum that is different
from the predominantly BAC subtype. Based on all the above
findings taken together, the profiles of factors involved in the
polarization of M2 macrophages, including MCP-1 and IL-
10, may be different in the predominant BAC subtype and
solid subtype.
Because CD204-positive macrophage infiltration was
also related to several factors involved in local invasion,
including lymphatic permeation, vessel invasion, and pleural
invasion, we speculate that CD204-positive macrophages
contribute to local invasion by cancer cells. Practically,
TAMs are important producers of proteases, including matrix
metalloproteinases, and of a wide variety of growth factors
such as fibroblast growth factor (FGF) and epidermal growth
factor (EGF) receptor family ligands that can stimulate the
growth and motility of tumor cells.9 TAMs have been re-
ported to be the most significant source of EGF in tumors,30
and they are associated with EGF receptor expression and
poor outcome in breast cancer.31 Pollard et al.9,32 showed that
tumor cells responded to macrophage-produced EGF ligands
TABLE 3. Prognostic Significance for Overall Survival
(Univariate Analysis)
Characteristics
Patient
(N  170) 5-yr
Survival
(%) p*No. Percentage
Age
Median, yr
(range)
63 (33–85) 0.0048†
70 yr 122 71.8 79.3
70 yr 48 28.2 62.5
Gender
Male 85 50.0 67.9 0.0019†
Female 85 50.0 81.1
Smoking history
Never 81 47.6 85.2 0.0002†
Former or current 89 52.4 64.8
CEA
5.0 104 61.5 83.5 0.0150†
5.0 65 38.5 60.0
Differentiation
Well 86 50.6 89.4 0.0001†
Moderately or
poorly
84 49.4 59.5
Pathological stage
IA 98 57.6 86.6 0.0001†
IB–IIIA 72 42.4 58.4
T status
T1 109 64.1 81.4 0.0001†
T2–3 61 35.9 62.3
Nodal involvement
N() 130 76.5 85.4 0.0001†
N() 40 23.5 38.5
Lymphatic permeation
Ly() 108 63.5 87.0 0.0001†
Ly() 62 36.5 50.9
Vessel invasion
V() 105 61.8 89.5 0.0001†
V() 65 38.2 50.0
Pleural invasion
PL() 121 71.2 82.5 0.0001†
PL() 49 28.8 55.1
CD68-positive
macrophage
Below median 82 48.2 81.6 0.0789
Above median 88 51.8 67.8
CD204-positive
macrophage
Below median 81 47.6 88.9 0.0073†
Above median 89 52.4 61.4
*Log-rank test.
†p  0.05.
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FIGURE 4. Kaplan-Meier analysis of
overall survival. Kaplan-Meier analysis
of overall survival according to the
level of infiltration by CD68 macro-
phages (A) and by CD204 macro-
phages (B). Data were dichotomized
at the median value for each parame-
ter.
FIGURE 5. Correlations between the
levels of expression of factors and
numbers of CD204 macrophages. A,
The levels of expression shown are
ratios of expression in cancer tissue to
expression in noncancerous tissue.
The ratios are expressed as means 
standard deviation. Expression of
IL-10 (p  0.0031) and MCP-1 (p 
0.0031) was significantly higher in the
CD204high group (n  9) than in the
CD204low group (n  9). The differ-
ences in expression of IL-6 (p 
0.122), IL-12a (p  0.666), IL-12b
(p  0.436), M-CSF (p  0.284), and
IFN-gamma-. (p  0.233) were not
significant. B, Correlations between
levels of IL-10 and MCP-1 expression
(ratios of expression in cancer tissue
to expression in noncancerous tissue)
and the distribution of CD204 mac-
rophages of each case are shown. The
numbers of CD204-positive macro-
phages were significantly correlated
with the increases in the ratios of
IL-10 expression (r2  0.580, p 
0.001) and MCP-1 expression (r2 
0.641, p  0.001).
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in vivo by chemotaxis and invasion and that the macrophages
were often associated with vessels. These findings suggest
that CD204-positive macrophages provide chemotactic sig-
nals that recruit tumor cells to blood vessels and enhance their
egress into the vasculature.
In conclusion, the results of this study demonstrated
that CD204-positive macrophages in cancer stroma would be
the marker of tumor-promoting macrophages. The tumor
microenvironment may also be important in terms of the
treatment of lung cancer. Reducing the number of TAMs in
the tumor stroma in an animal model of breast cancer has
been found to effectively alter the tumor microenvironment
involved in tumor angiogenesis and progression and to mark-
edly suppressed tumor growth and metastasis.33 Bak et al.34
demonstrated that anti-CD204 immunotoxin reduced the peri-
toneal tumor burden and accumulation of ascitic fluid in a
murine model of ovarian cancer. These findings support the
feasibility of possible new immunotherapy for adenocarci-
noma of the lung that targets CD204-positive macrophages.
Thus, more accurate insight into the role of CD204-positive
macrophages and consideration of the local microenviron-
ment in regulating the functions of this type of macrophages
is needed and has important implications.
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